...
bntx-img

BioNTech SE, Common Stock

BNTX

NSQ

$87.21

+$0.5

(0.58%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$20.73B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
20.57
Volume info-icon
This is the total number of shares traded during the most recent trading day.
348.30K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
581.54K
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$85.21 L
$125.83 H
$87.21

About BioNTech SE, Common Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBNTXSectorS&P500
1-Week Return0.46%0.71%1.64%
1-Month Return-4.9%-4%-2.94%
3-Month Return-8.01%0.84%3.53%
6-Month Return-9.76%12.62%22.95%
1-Year Return-21.15%7.99%26.43%
3-Year Return-49.4%18.97%26.19%
5-Year Return520.54%71.39%86.42%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue108.59M482.32M18.98B17.31B3.82B[{"date":"2019-12-31","value":0.57,"profit":true},{"date":"2020-12-31","value":2.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.22,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true}]
Cost of Revenue243.83M704.36M3.86B4.53B599.80M[{"date":"2019-12-31","value":5.38,"profit":true},{"date":"2020-12-31","value":15.54,"profit":true},{"date":"2021-12-31","value":85.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.23,"profit":true}]
Gross Profit(135.24M)(222.04M)15.12B12.78B3.22B[{"date":"2019-12-31","value":-0.89,"profit":false},{"date":"2020-12-31","value":-1.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.54,"profit":true},{"date":"2023-12-31","value":21.3,"profit":true}]
Gross Margin(124.54%)(46.03%)79.66%73.82%84.29%[{"date":"2019-12-31","value":-147.75,"profit":false},{"date":"2020-12-31","value":-54.61,"profit":false},{"date":"2021-12-31","value":94.5,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses46.28M(139.62M)200.10M135.90M2.31B[{"date":"2019-12-31","value":2,"profit":true},{"date":"2020-12-31","value":-6.03,"profit":false},{"date":"2021-12-31","value":8.64,"profit":true},{"date":"2022-12-31","value":5.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(181.52M)(82.42M)15.28B12.64B690.40M[{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.54,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.72,"profit":true},{"date":"2023-12-31","value":4.52,"profit":true}]
Total Non-Operating Income/Expense1.81M(66.87M)(263.20M)622.80M281.90M[{"date":"2019-12-31","value":0.29,"profit":true},{"date":"2020-12-31","value":-10.74,"profit":false},{"date":"2021-12-31","value":-42.26,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.26,"profit":true}]
Pre-Tax Income(179.44M)(145.80M)15.05B12.95B1.19B[{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.09,"profit":true},{"date":"2023-12-31","value":7.88,"profit":true}]
Income Taxes(268.00K)(161.00M)4.75B3.52B255.80M[{"date":"2019-12-31","value":-0.01,"profit":false},{"date":"2020-12-31","value":-3.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.04,"profit":true},{"date":"2023-12-31","value":5.38,"profit":true}]
Income After Taxes(179.17M)15.20M10.29B9.43B930.30M[{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}]
Income From Continuous Operations(179.17M)15.20M10.29B9.43B930.30M[{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(179.17M)15.20M10.29B9.43B930.30M[{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}]
EPS (Diluted)(0.39)0.0739.6936.933.83[{"date":"2019-12-31","value":-0.98,"profit":false},{"date":"2020-12-31","value":0.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":9.65,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BNTX
Cash Ratio 7.99
Current Ratio 9.43
Quick Ratio 9.26

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BNTX
ROA (LTM) 2.62%
ROE (LTM) 4.62%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BNTX
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.14

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BNTX
Trailing PE 21.15
Forward PE 7.04
P/S (TTM) 5.46
P/B 0.96
Price/FCF 32
EV/R 0.87
EV/Ebitda 3.06
PEG NM

News

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies'' blockbuster COVID-19 vaccines.

25 Apr, 2024 a 1:39 pm Reuters

Covid-19 vaccine rivals face off as Moderna sues Pfizer and BioNTech

Pfizer and BioNTech are locked in a legal dispute with vaccine maker Moderna at the High Court in London over the use of messenger RNA (mRNA) technology in coronavirus jabs.

24 Apr, 2024 a 8:00 am Daily Mail Online

Covid jab rivals face off in court as US firm Moderna sues Pfizer and BioNTech for ''infringing on its patent'' for life-saving mRNA vaccines

Pfizer and BioNTech are locked in a legal dispute with vaccine maker Moderna at the High Court in London over the use of messenger RNA (mRNA) technology in coronavirus jabs.

23 Apr, 2024 a 5:18 pm Daily Mail Online

Rival Covid-19 jab developers face off in High Court patent trial

Moderna, Pfizer and BioNTech are in a dispute over the rights to life-saving vaccine technology patents.

23 Apr, 2024 a 12:27 pm Evening Standard

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Pfizer and BioNTech asked a London court to revoke rival Moderna''s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

23 Apr, 2024 a 12:03 pm The Korea Times

Moderna, Pfizer/BioNTech set for UK court clash over Covid jab patents

The hearing is due to start at the High Court in London

23 Apr, 2024 a 6:01 am Zawya

Moderna, Pfizer/BioNTech in UK court clash over Covid jab patents

Moderna claims that it is owed compensation for the infringement on its advanced mRNA technology.

23 Apr, 2024 a 5:33 am Free Malaysia Today

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 | BNTX Stock News

BioNTech SE (Nasdaq: BNTX) will report its first-quarter 2024 financial results on May 6, 2024. The Company will host a conference call and webcast to discuss the results and provide a corporate update for investors, financial analysts, and the general public.

22 Apr, 2024 a 10:45 am Stock Titan

NIH Refuses To Release Details Of COVID-19 Vaccine Royalty Agreement

NIH Refuses To Release Details Of COVID-19 Vaccine Royalty Agreement Authored by Zachary Stieber via The Epoch Times (emphasis ours), The U.S. National Institutes of Health (NIH) is refusing to release additional information about an agreement it reached over a COVID-19 vaccine that has earned it at least $400 million. Syringes of Moderna COVID-19 vaccines at a vaccination site in Los Angeles, on Feb. 16, 2021. (Apu Gomes/AFP via Getty Images) The NIH declined to provide any materials in response to a Freedom of Information Act request from The Epoch Times. “ The NIH withholds the entirety of the records as they are protected from release ,” Gorka Garcia-Malene, an NIH officer, told The Epoch Times in a letter. She cited an exemption outlined in the act that allows government agencies to partially or fully withhold information. “In this case, exemption 3 incorporates 35 U.S.C. 209 (f), which reads in relevant part, ‘No Federal agency shall grant any license under a patent or patent application on a federally owned invention unless the person requesting the license has supplied the agency with a plan for development or marketing of the invention, except that any such plan shall be treated by the Federal agency as commercial and financial information obtained from a person and privileged and confidential and not subject to disclosure under section 552 of title 5,’” Ms.

20 Apr, 2024 a 2:40 am Zero Hedge

FAQs

What is BioNTech SE share price today?

BioNTech SE (BNTX) share price today is $87.21

Can Indians buy BioNTech SE shares?

Yes, Indians can buy shares of BioNTech SE (BNTX) on Vested. To buy BioNTech SE from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BioNTech SE be purchased?

Yes, you can purchase fractional shares of BioNTech SE (BNTX) via the Vested app. You can start investing in BioNTech SE (BNTX) with a minimum investment of $1.

How to invest in BioNTech SE shares from India?

You can invest in shares of BioNTech SE (BNTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in BNTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BioNTech SE shares
What is BioNTech SE 52-week high and low stock price?

The 52-week high price of BioNTech SE (BNTX) is $125.83. The 52-week low price of BioNTech SE (BNTX) is $85.21.

What is BioNTech SE price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of BioNTech SE (BNTX) is 20.57

What is BioNTech SE price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BioNTech SE (BNTX) is 0.96

What is BioNTech SE dividend yield?

The dividend yield of BioNTech SE (BNTX) is 0.00%

What is the Market Cap of BioNTech SE?

The market capitalization of BioNTech SE (BNTX) is $20.73B

What is BioNTech SE’s stock symbol?

The stock symbol (or ticker) of BioNTech SE is BNTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top